Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Lysosomal alpha-glucosidase is an enzyme encoded by the GAA gene. It is essential for the degradation of glycogen to glucose in lysosomes. Defects in this gene lead to glycogen storage disease II or Pompe disease.
The Lysosomal Alpha – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Lysosomal Alpha, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lysosomal Alpha and features dormant and discontinued projects.
Key Therapy Areas in the Lysosomal Alpha Pipeline Drugs Market
The key therapy area in the Lysosomal Alpha pipeline drugs market is Metabolic Disorders.
Key MoA in the Lysosomal Alpha Pipeline Drugs Market
The key mechanisms of action in the Lysosomal Alpha pipeline drugs market are Lysosomal Alpha Glucosidase Replacement, and Lysosomal Alpha Glucosidase Activator.
Lysosomal Alpha Pipeline Drugs Market Analysis, by MoA
To get more insights on key MoA, download a free sample report
Lysosomal Alpha Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Lysosomal Alpha pipeline drugs market are Subcutaneous, Intravenous, Oral, and Intramuscular.
Lysosomal Alpha Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Lysosomal Alpha Pipeline Drugs Market
The key molecule types in the Lysosomal Alpha pipeline drugs market are Small Molecule, Recombinant Enzyme, Fusion Protein, Gene Modified Cell Therapy, and Gene Therapy among others.
Lysosomal Alpha Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Lysosomal Alpha Pipeline Drugs Market
The major companies in the Lysosomal Alpha pipeline drugs market are Amicus Therapeutics Inc, Asklepios BioPharmaceutical Inc, Astellas Gene Therapies, AVROBIO Inc, Denali Therapeutics Inc, eleva GmbH, Equaly SA, Genzyme Corp, ImmunityBio Inc, and M6P Therapeutics among others.
Lysosomal Alpha Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Lysosomal Alpha Pipeline Drugs Market Overview
Key Therapy Areas | Metabolic Disorders |
Key Mechanisms of action | Lysosomal Alpha Glucosidase Replacement, and Lysosomal Alpha Glucosidase Activator |
Key Routes of Administration | Subcutaneous, Intravenous, Oral, and Intramuscular |
Key molecule types | Small Molecule, Recombinant Enzyme, Fusion Protein, Gene Modified Cell Therapy, and Gene Therapy |
Major companies | Amicus Therapeutics Inc, Asklepios BioPharmaceutical Inc, Astellas Gene Therapies, AVROBIO Inc, Denali Therapeutics Inc, eleva GmbH, Equaly SA, Genzyme Corp, ImmunityBio Inc, and M6P Therapeutics |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Lysosomal Alpha
- The pipeline guide reviews pipeline therapeutics for Lysosomal Alpha by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Lysosomal Alpha therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Lysosomal Alpha therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Lysosomal Alpha
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Lysosomal Alpha
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Lysosomal Alpha pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Asklepios BioPharmaceutical Inc
Astellas Gene Therapies
AVROBIO Inc
Denali Therapeutics Inc
Equaly SA
Genzyme Corp
ImmunityBio Inc
JCR Pharmaceuticals Co Ltd
M6P Therapeutics
NanoMedSyn SAS
Oxyrane Belgium NV
Pharming Group NV
Spark Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the Lysosomal Alpha pipeline drugs market?
The key therapy area in the Lysosomal Alpha pipeline drugs market is Metabolic Disorders.
-
What are the key mechanisms of action in the Lysosomal Alpha pipeline drugs market?
The key mechanisms of action in the Lysosomal Alpha pipeline drugs market are Lysosomal Alpha Glucosidase Replacement, and Lysosomal Alpha Glucosidase Activator.
-
What are the key routes of administration in the Lysosomal Alpha pipeline drugs market?
The key routes of administration in the Lysosomal Alpha pipeline drugs market are Subcutaneous, Intravenous, Oral, and Intramuscular.
-
What are the key molecule types in the Lysosomal Alpha pipeline drugs market?
The key molecule types in the Lysosomal Alpha pipeline drugs market are Small Molecule, Recombinant Enzyme, Fusion Protein, Gene Modified Cell Therapy, and Gene Therapy.
-
What are the major companies in the Lysosomal Alpha pipeline drugs market?
The major companies in the Lysosomal Alpha pipeline drugs market are Amicus Therapeutics Inc, Asklepios BioPharmaceutical Inc, Astellas Gene Therapies, AVROBIO Inc, Denali Therapeutics Inc, eleva GmbH, Equaly SA, Genzyme Corp, ImmunityBio Inc, and M6P Therapeutics.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.